| 1 |
35551173 | Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration. | 2022 May 13 |
2 |
| 2 |
33294858 | A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. | 2020 Nov 17 |
2 |
| 3 |
26148346 | Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model. | 2015 Jul-Aug |
6 |
| 4 |
22301676 | Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. | 2012 Jul |
1 |
| 5 |
22492694 | Inhibition of Syk activity by R788 in platelets prevents remote lung tissue damage after mesenteric ischemia-reperfusion injury. | 2012 Jun 15 |
1 |
| 6 |
21700926 | The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. | 2011 Sep |
3 |
| 7 |
20716772 | The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. | 2010 Dec 2 |
1 |